Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):


	September 30, 2026						December 31, 2025						Weighted Average Remaining Amortization Period (Years)
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Percepta product technology	$	16,000	$	(12,267)	$	3,733	$	16,000	$	(11,467)	$	4,533	3.5
Prosigna product technology	4,120		(1,877)		2,243		4,120		(1,671)		2,449		8.2
Decipher product technology	97,300		(50,672)		46,628		97,300		(43,558)		53,742		5.8
Decipher trade names	4,000		(4,000)		—		4,000		(3,843)		157
C2i developed technology	31,500		(4,636)		26,864		25,300		(3,233)		22,067		12.9
Manufacturing know-how	9,000		(250)		8,750		—		—		—		3.0
Convergent developed technology	95,900		(206)		95,694		—		—		—		15.0
Convergent trademarks and tradenames	60		(1)		59		—		—		—		5.0
Convergent customer relationships	920		(8)		912		—		—		—		5.0
Total finite-lived intangibles	258,800		(73,917)		184,883		146,720		(63,772)		82,948		11.4
In-process research and development	—		—		—		6,200		—		6,200
Total intangible assets	$	258,800	$	(73,917)	$	184,883	$	152,920	$	(63,772)	$	89,148

Acquisition-related intangibles are generally finite-lived and are carried at cost less accumulated amortization. Amortization of the finite-lived intangible assets is recognized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized. During the second quarter of 2026 following the launch of TrueMRD, in-process research and development intangibles of $6.2 million were reclassified to C2i developed technology intangibles and is being amortized over its estimated useful life.

On August 31, 2026, the Company closed a transaction to acquire certain assets for $5.3 million in cash and two mandatory annual license fee payments of $3.0 million due following the first and second anniversaries of the closing date. The acquisition was accounted for as a business combination and resulted in the recording of $9.0 million of intangible assets for manufacturing know-how.

Amortization of $3.7 million and $3.3 million was recognized for the three months ended September 30, 2026 and 2025, respectively, and an expense of $10.1 million and $9.8 million was recognized for the nine months ended September 30, 2026 and 2025, respectively.

The Company concluded, during the second quarter of 2025, that the long-lived assets of the Veracyte SAS asset group were not recoverable. As a result, the Company recorded a $20.5 million non-cash impairment charge for the nine months

ended September 30, 2025. The impairment related primarily to the Company's right-of-use assets; property, plant, and equipment; and certain tax credits. The impairment is included within the impairment of assets in the consolidated statement of operations.

Effective August 1, 2025, the Company ceased to have a controlling interest in its wholly-owned French subsidiary, Veracyte SAS. Accordingly, the Company derecognized the related assets and liabilities from its condensed consolidated financial statements. Prior to deconsolidation, the operating results and cash flows of Veracyte SAS were included in the Company’s condensed consolidated financial statements. In accordance with ASC 810, Consolidation, the Company recognized a loss on deconsolidation of approximately $6.7 million, which is included in other income, net in the condensed consolidated statements of operations for the three months ended September 30, 2025.